Krsnaa Diagnostics

Krsnaa Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Krsnaa Diagnostics (KRSNAA.NS) as of Oct 31, 2026 is -92.93 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -50.64 % — a change of 83.51% (lower).

FCF Conversion

-92.93 %

YoY

83.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Krsnaa Diagnostics is 2026 -92.93 % . FCF Conversion Rate (FCF/EBITDA) of Krsnaa Diagnostics was 2025 -50.64 % . It decreases by 83.51% lower compared to the previous year.

The Krsnaa Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
71.50 INR
Jan 1, 2020
34.78 INR
Jan 1, 2021
19.31 INR
Jan 1, 2022
-5.55 INR
Jan 1, 2023
-104.75 INR
Jan 1, 2024
-298.30 INR
Jan 1, 2025
-50.64 INR
Jan 1, 2026
-92.93 INR
The Krsnaa Diagnostics FCF Conversion history
YEARFCF ConversionYoY
-92.93 %+83.51%
-50.64 %-83.02%
-298.30 %+184.78%
-104.75 %+1,787.59%
-5.55 %-128.73%
19.31 %-44.47%
34.78 %-51.35%
71.50 %-25.66%
96.18 %-141.90%
-229.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Krsnaa Diagnostics Stock analysis

What does Krsnaa Diagnostics do? Krsnaa Diagnostics Ltd provides diagnostic services across India, including radiology and pathology through X-Ray, CT scan, MRI, mammography, and tele-reporting. The company offers lab services for blood and urine investigations, supported by technology that aids healthcare professionals in diagnosing medical conditions. Its health packages include Ayaksham-Total, Bone Health-Advance, Fever Profile-Basic, Hypertension Profile, Menopause Profile-Advance, and Polycystic Ovaries Screening (PCOS). The firm serves public and private hospitals, medical colleges, and community health centers as its primary customers. The company generates revenue through diagnostic service fees charged to hospitals, medical colleges, and community health centers. These institutions purchase the diagnostic services for their patients, utilizing Krsnaa's imaging and lab capabilities. The health packages are also sold to these institutions for patient care programs, contributing to the company's revenue streams. Krsnaa Diagnostics Ltd's product portfolio focuses on medical imaging and laboratory testing, targeting healthcare providers and institutions. The primary segments served are public and private hospitals, medical colleges, and community health centers, which rely on the company's diagnostic solutions for patient diagnostics and treatment planning. Krsnaa Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Krsnaa Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Krsnaa Diagnostics is -92.93 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Krsnaa Diagnostics changed from -50.64 % to -92.93 %, representing a 83.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Krsnaa Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Krsnaa Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Krsnaa Diagnostics

All Key Metrics — Krsnaa Diagnostics